Zhitong Financial APP learned that a total of three new shares were listed on July 20, namely, N Zhixin (301512.SZ) of gem, N Kangpeng (688602.SH) of Science and Technology Innovation Board, and N Jinbo (832982.BJ) of the Beijing Stock Exchange. Among them, the new stock Zhixin precision trading rose 136%, triggering a temporary stop. Jinbo Bio, which was also listed today, rose more than 190% in morning trading, with a profit of more than 9000 yuan, making it the largest meat pick on the Beijing Stock Exchange this year. Another new stock, Kangpeng Technology, rose more than 50% at the start of trading, but fell back to 38.57% by the end of the day.

Specifically, Zhixin Precision IPO IPO price is 39.66 yuan per share, offering price-to-earnings ratio of 27.51 times, industry price-to-earnings ratio of 30.61 times. By the end of the day, the stock was up 116.87% and 136% in intraday trading, triggering a temporary suspension. According to the highest intraday price of 93.60 yuan, the stock made a maximum profit of more than 26000 yuan (500 shares).

According to the prospectus, Zhixin Precision focuses on machine vision and industrial software development, and is mainly engaged in the research and development, design, production, sales and related technical services of automation equipment, automation lines and fixtures. And provide software and hardware integrated system solutions for customers to achieve intelligent production. After years of development and accumulation and continuous R & D and innovation, the company has industry-leading machine vision, precision motion control, general software platform and other technologies.

On the financial front, Zhixin's operating income in 2020,2021 and 2022 was about 399 million yuan, 491 million yuan and 547 million yuan respectively. The company's net profit is about 81.8169 million yuan, 94.6647 million yuan and 89.0213 million yuan respectively.

Jinbo Bio, which is listed on the Beijing Stock Exchange, rose sharply at the start of trading today, with an opening price of 117 yuan. it rose more than 190% in the morning and made a profit of more than 9000 yuan, making it the largest meat signature on the Beijing Stock Exchange this year. As of today's close, Jinbo Bio reported 127.25 yuan, an increase of 159.69%.

It is worth mentioning that Jinbo Bio has adjusted the reserve price twice. Jinbo Bio first announced a reserve price of 117 yuan per share, the highest in the history of Beijiao Stock Exchange. Before the meeting, Jinbo Bio had substantially reduced the issue price to 50 yuan per share. After the meeting, Jinbo Bio adjusted the reserve price of the issue for the second time, and the reserve price was adjusted to 49 yuan per share, which was only reduced by 1 yuan. Despite two price adjustments, Jinbo Bio is still the highest IPO price of new shares on the Beijing Stock Exchange.

Jinbo Biology is a high-tech enterprise which applies cutting-edge technologies such as structural biology and protein rational design, and systematically engages in basic research such as structural analysis and functional discovery of functional proteins around the field of new materials for life and health and antivirus. and the use of synthetic biology and other methods to achieve large-scale production of functional proteins, but also a national "specialized and new" small giant enterprise.

In terms of finance, in 2020,2021 and 2022, Jinbo realized operating income of about 161 million yuan, 233 million yuan and 390 million yuan respectively. In the same period, the net profits attributed to the owners of the parent company were about 31.9484 million yuan, 57.3873 million yuan and 109 million yuan respectively.

The initial price of Kangpeng Technology of Shanghai Stock Exchange Kechuang Board is 8.66 yuan per share, with a price-to-earnings ratio of 26.92 times. At one point, the company rose more than 60% on its first day of trading. As of today's close, Kangpeng Science and Technology reported 12.00 yuan per share, up 38.57%.

Kangpeng Technology is a technology-driven enterprise deeply engaged in the field of fine chemicals, mainly engaged in the research and development, production and sales of fine chemicals. The products are mainly new materials and pharmaceutical and pesticide chemicals, and new materials mainly cover display materials, new energy battery materials and electronic chemicals, silicone materials and other fields. Selling customized pharmaceutical and pesticide chemicals to the downstream belongs to CDMO business.

On the financial side, Kangpeng's operating income was about 629 million yuan, 1.005 billion yuan and 1.238 billion yuan in 2020,2021 and 2022, respectively. In the same period, the net profits attributed to the owners of the parent company were about 90.2767 million yuan, 134 million yuan and 181 million yuan respectively.